Princeton, NJ, May 02, 2017 --(PR.com
)-- ADEs are the fourth leading cause of death nationwide, after heart disease, cancer and stroke. Approximately 5 percent of hospital admissions are due to adverse drug events and patients who experienced ADEs were hospitalized an average of 8 to 12 days longer.(1)
Available research shows that much of the variability observed in patient responses to drug therapies is a result of genetics. Pharmacogenetic testing identifies this variability and helps you in the clinical management of your patients.
Using the results from pharmacogenetic testing, prescribing becomes individualized either through a dose adjustment, or selection of an alternative therapy.
This tailored approach results in better efficacy and fewer adverse drug reactions.
A patient’s metabolic status is often affected by a change in a single base pair for a gene that codes for a drug-metabolizing enzyme. This gives rise to such patient subgroups as poor metabolizers, rapid metabolizers and ultra-rapid metabolizers. Each of these subgroups differ in their ability to metabolize certain drugs. With this insight, physicians achieve greater medication tolerability.
Factors to consider when selecting a pharmacogenetic testing solution:
Is there consistent quality control applied to the testing process?
Is there scientific rigor applied to the genotyping methodology?
Are clinically actionable insights offered that allow decisions at the point of care?
Who to test?
- Starting any new medication
- Experiencing unwanted side effects from any medication
- On chronic pain medication and/or antidepressants
- Taking two or more medications
- Diagnosed with complex chronic diseases:
- Cardiovascular problems
- On medications with possible risk of blood clots
- On chronic beta blocker, SSRIs, antiarrythmic therapy
- Preparing for a surgical procedure
- Currently taking Plavix or Coumadin
- Taking certain statin drugs or are candidates for such drugs
Testing is covered by Medicare and most major insurance companies.
Emgenex, a New Jersey Based company offers GenoScrobe and GenoScribe Live software for clinical testing option to providers.
GenoScribe: An extensive and unprecedented pharmacogenetic testing service to help physicians personalize treatment and medications based on a patient's genetics.
GenoScribe Live: Going beyond pharmacogenetics, GenoScribe Live is a comprehensive medication risk management tool powered by data, analytics and scientific research.
GenoScribe Live factors in Pharmacogenetics, Demographics, lifestyle, and medical conditions so you can assess the treatment plan with the least amount of risk while still accomplishing the intended therapy.
References: (1) Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008; 42(7):1017-25.
We recognize the challenges in today’s complex and fragmented healthcare environment. Our robust, personalized and comprehensive medication risk management solutions provide the tools needed to make informed decisions at the point of care. We leverage innovative technology to transform workflow and enhance patient, physician and health system integration, resulting in coordinated and better quality care.www.emgenex.com